AbbVie Inc (ABBV) - Total Liabilities
Based on the latest financial reports, AbbVie Inc (ABBV) has total liabilities worth $108.96 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AbbVie Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
AbbVie Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how AbbVie Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of AbbVie Inc.
AbbVie Inc Competitors by Total Liabilities
The table below lists competitors of AbbVie Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Berkshire Hathaway Inc
NYSE:BRK-A
|
USA | $522.82 Billion |
|
The Coca-Cola Company
NYSE:KO
|
USA | $69.61 Billion |
|
Caterpillar Inc
NYSE:CAT
|
USA | $77.27 Billion |
|
Chevron Corp
NYSE:CVX
|
USA | $140.18 Billion |
|
HSBC Holdings plc
MX:HBCN
|
Mexico | MX$3.04 Trillion |
|
Procter & Gamble Company
NYSE:PG
|
USA | $73.97 Billion |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
USA | $203.78 Billion |
|
Lam Research Corp
NASDAQ:LRCX
|
USA | $10.21 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down AbbVie Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ABBV equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AbbVie Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AbbVie Inc (2010–2025)
The table below shows the annual total liabilities of AbbVie Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $137.19 Billion | +4.09% |
| 2024-12-31 | $131.80 Billion | +6.02% |
| 2023-12-31 | $124.31 Billion | +2.30% |
| 2022-12-31 | $121.52 Billion | -7.30% |
| 2021-12-31 | $131.09 Billion | -4.64% |
| 2020-12-31 | $137.47 Billion | +41.30% |
| 2019-12-31 | $97.29 Billion | +43.50% |
| 2018-12-31 | $67.80 Billion | +3.21% |
| 2017-12-31 | $65.69 Billion | +6.88% |
| 2016-12-31 | $61.46 Billion | +25.17% |
| 2015-12-31 | $49.10 Billion | +90.54% |
| 2014-12-31 | $25.77 Billion | +4.31% |
| 2013-12-31 | $24.71 Billion | +4.49% |
| 2012-12-31 | $23.64 Billion | +211.57% |
| 2011-12-31 | $7.59 Billion | +39.72% |
| 2010-12-31 | $5.43 Billion | -- |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more